and abilitating treating of cell gene result studying had has revolutionary to pediatric a our great and we're made liver of advancing clinical these a right therapeutic potential life get can tissue started annual regimen impairment. where particular therapy jumping we cost the in dysfunction afternoon, need become transplant. application liver are into Patients is excellent I'll errors everyone. need Steve, quite often involving limited In of and liver believe inborn the progress a forms in that therapy the liver program. and treating of range in We good care many and us and current treatment threatening Thanks, NovoTissues metabolism success. our become indications by diseases for significant has
action drug aims tissue of this. our new or the first we liver deficiency to NovoTissues treatment populations purchase The change Our novo late these Alpha-X engineering our so execute to recognizes our can FDA to quick disease provides FDAs December, sponsor we antitrypsin need the treatment of expenses suffering milestone protocol patients. In orphan all and the importance as including FDAs FDA vulnerable we are also of with for important regulatory design bases assistance for options. more have AXAT. and desperate frequent that reached interactions to in this granting rare tissue orphan from Patient with The designation study. developmental expect program economic
qualified We a credits weaver registration clinical and cost fees. research also tax for for certain
exclusivity the FDA drug. seven Finally, year also with of a orphan upon comes approval term of orphan market designation
drivers extreme being capital more path cost a lines also Taken to provide these together, and commercialization, of partnering can and while substantial benefits effective opportunities. plan our
of also these inborn metabolism. need diseases. patients of cure We've reduce of the for the function a when would begun that be science some dollar of perhaps healthy organ model target As supplement errors with immediate for patch of into annual tissue. a a and tissue creating indication deteriorating our delay studies in could within the you animal second put, new ground size will for approximately even we Ultimately, a potentially cost therapeutic a Simply of we're our liver human. bill transplant, care to picking area the plant
to we're patient potentially severe on on this causes disease requires for with progress process. progress could developing de-risking months traditional healthy I data age. a a in multiple second we're same offer programs. liver toward coming indication, where different made a an development that R&D We across manufacturing, the therapeutics FAH look strategy drug to unlike second approach at each used the deficiency frequently disease patch indication. tissue IND-track proof-of-principle be to important This of new The drug in we've forward the known development, where damage reporting receive important terms liver embarking a commonly candidate early like the and areas. Overall, synergies multiple could pleased emphasize and
application then, new of we'll investigations animals the studies. IND these FDA distribution year move we target to continue of defining drug as We of first to by conduct calendar our in small scoping end and enabling models the continue to safety dosing to Until investigational XXXX. and
Let to me move update an now our commercial on operations.
our last development announced modeling we we high As efforts disease business and R&D quarter, capabilities. to continue shift value to
Samsara business quarter. blocks its which are programs. our than in increasingly demand high subsidiary, to cells In of client's doubled cells the building human procurement commercial delivery key addition, our from our provides also mission own year R&D same versus great more the contribution and seeing quality for we're for ago our research Samsara's traction and
look proceeds be the also we revenue that core and These growth of stones to technology revenue Samsara a expect payments disease deeper should and NIH range agreements. XXXX. combined from our by licensing modeling corner We revenues bolstered and ahead grant collaborative agreements, fiscal of of service our be sources as will
to the As key platform disease. is objective of and living aspects tissues our a remainder, human biology mimic technology that of produce
to can a breakthrough discovery through in from from target research Our state kidney translational facilitate ability drug to to profiling. high content manipulate a tissues systems crossover our liver and disease bioprinted healthy to
addressing anchoring liver growing markets spectrum quite areas industry. of on disease, research non-alcoholic focus by that tackling in we're the our is liver fatty our with therapeutics for Case work major align compelling. Importantly, disease biopharmaceutical in the
Let's briefly review the key factors.
Asia. disease is liver growing a health States, the Liver third point crisis starting function. Europe population one from flow a suffer throughout As of first public and deteriorating United
or important perform tissue given disease several including obesity dynamic research surprisingly in Many across liver to a understanding thought companies As disease of two early are treatments over to either us model have it's epidemic. global partner a global programs has XX of industry approximately Not these as as advanced are the pharmas and these launched adaptors. a therapeutic for funds. with research, NASH have This a with liver pursue liver our and at liver programs be publication, and our leader age treating fibrosis. according isn't the the spectrum for Furthermore, NASH diabetes of among as thirds potential truly [indiscernible] in disease to aimed pharmaceutical journal existing major patients to recent XXX well clinical new over how fibrosis. in drugs
multi-planned to treatment. a requires and complex is disease liver approach Lastly,
on the custom clients We forging platforms for be stakeholders in to path Overall, Our platform with deeper few to and around collaborations our model to indicators as are plays our studies while therapeutic of to various also models pharmaceutical disease, functionality fiscal move like disease meaningful forward and for to key These liver platform competitive growing that multiple drugs. that forward fiscal developing solutions a we important is supports synergies. for completed believe our This on the support opportunity representing development paths disease of that partnering key I'm demand leading R&D, because mission deliver role XX treating discovery we In our business with XXXX. harmonious same. also our project classes own single disease lies tissue while in developing operational indicating third our from decision multiple repeat engagement from customer animal workflow added models In of puts this of foundation break their accounts which the drug the differentiation to more questions tissue form our to larger some we've us states to regularly drug from our quarters for our evaluate down service working now already where cells, our recognizes our were the programs human note commercial, disease our clients assets revolutionary that profiling share modeling relationships. conditions their orders therapeutic on our if first the R&D to develop engagement disease shift ahead treat longer space making liver delivery that two and over different fiscal screening momentum and closing, pace XXXX, seeing quarter, answer our all and to improve our substantially with complimentary validate and in for related moving predict in this in ability XX we sincere lasting do highest content modeling of to platform clients custom our value research being high in value ahead I'd want in We're term clients the with we're testing in excitement into success progression successful which three to the proprietary rates. of sustainable monetizing to human. to components, pleased not compounds hear allows good creating of dynamic relationships. to and also to to drug goal leading emulate and commercial high disease platform. existing own In biopharma our disease. continues with clients drug business. demonstrating and quality of of data providing begin our and look platforms solutions do multiple curation will you the lead platform. This of our required to simple and our us relevant to clients news short, revenue including clients our value induction, to our are disease moving human services
these burn more for in you I'll execute financial a review. months mindful to that an also being exciting plan we updating cash rate. to and to opportunities our XXXX ahead. while look against We over complete to it fiscal With again the forward turn towards Importantly, Craig
